Sana Biotechnology Inc (SANA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.08 (-0.65%), Market cap $0.85B, 52-week low–high $1.99 ~ $5.92.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologi
Financial statements, price targets, institutional (13F) holdings and related news for Sana Biotechnology Inc are updated in real time on BlackAll Trade.
Sana Biotechnology Inc trades at $3.08 (-0.65%). Real-time quotes and charts are available on BlackAll Trade.
Sana Biotechnology Inc has a market cap of about $0.85B.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various thera